MaY, MacheskyLM: Fascin1 in carcinomas: its regulation and prognostic value. Int J Cancer, 2015; 137:2534–2544.
2.
TanVY, LewisSJ, AdamsJC, MartinRM: Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med, 2013; 11:52.
3.
MajchrzakK, Lo ReD, GajewskaM, et al.: Migrastatin analogues inhibit canine mammary cancer cell migration and invasion. PLoS One, 2013; 8:e76789.
4.
HanS, HuangJ, LiuB, et al.: Improving fascin inhibitors to block tumor cell migration and metastasis. Mol Oncol, 2016; 10:966–980.
5.
Conesa-ZamoraP, García-SolanoJ, García-GarcíaF, et al.: Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int J Cancer, 2013; 132:297–307.
6.
Alburquerque-GonzálezB, Bernabé-GarcíaM, Montoro-GarcíaS, et al.: New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Exp Mol Med, 2020; 52:281–292.
7.
Melo PereiraS, RibeiroR, LogarinhoE: Approaches towards longevity: reprogramming, senolysis, and improved mitotic competence as anti-aging therapies. Int J Mol Sci, 2019; 20:938.
8.
OzsvariB, NuttallJR, SotgiaF, LisantiMP: Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts. Aging (Albany NY), 2018; 10:3294–3307.
9.
FiorilloM, TóthF, SotgiaF, LisantiMP: Doxycycline, azithromycin and vitamin C (DAV): a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging (Albany NY), 2019; 11:2202–2216.
10.
RydholmH, von CorswantC, DenisonH, et al.: Reducing adverse effects during drug development: the example of lesogaberan and paresthesia. Clin Ther, 2016; 38:946–960.
11.
TianJ, DangH, HuA, XuW, KaufmanDL: Repurposing lesogaberan to promote human islet cell survival and β-cell replication. J Diabetes Res, 2017; 2017:6403539.
MinerK, LabitzkeK, LiuB, et al.: Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol, 2019; 10:51.
14.
SeoY, ParkJ, KimM, et al.: Inhibition of ANO1/TMEM16A chloride channel by idebenone and its cytotoxicity to cancer cell lines. PLoS One, 2015; 10:e0133656.
15.
GallosG, RemyKE, DanielssonJ, et al.: Functional expression of the TMEM16 family of calcium-activated chloride channels in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol, 2013; 305:L625–L634.
16.
KimK, KleinmanHK, LeeHJ, PahanK: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis, 2017; 12:113.
17.
CorbettGT, GonzalezFJ, PahanK: Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A, 2015; 112:8445–8450.
18.
ZhangH, GaoY, QiaoPF, ZhaoFL, YanY: Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR-α/PI3-K pathway. Int J Dev Neurosci, 2014; 38:223–231.
19.
LuoR, SuLY, LiG, et al.: Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 2020; 16:52–69.
20.
ChandraS, PahanK: Gemfibrozil, a lipid-lowering drug, lowers amyloid plaque pathology and enhances memory in a mouse model of Alzheimer's disease via peroxisome proliferator-activated receptor α. J Alzheimers Dis Rep, 2019; 3:149–168.
21.
LonsdaleD: Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. Med Sci Monit, 2004; 10:RA199–RA203.
22.
TaralloS, BeltramoE, BerroneE, DentelliP, PortaM: Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol, 2010; 47:105–111.
23.
LonsdaleD, ShambergerRJ, AudhyaT: Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett, 2002; 23:303–308.
24.
RinderHM, TraceyJB, SouhradaM, WangC, GagnierRP, WoodCC: Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J Clin Pharmacol, 2002; 42:881–886.
25.
de MeijerA, VollaardH, de MetzM, VerbruggenB, ThomasC, NovakovaI: Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. Clin Pharmacol Ther, 1999; 66:425–430.
26.
Van RynJ, Kink-EibandM, KuritschI, FeifelU, HanftG, WallensteinG: Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol, 2004; 44:777–784.
27.
ShahRR, BirdAP: MeCP2 mutations: progress towards understanding and treating Rett syndrome. Genome Med, 2017; 9:17.
28.
GogliottiRG, NiswenderCM: A coordinated attack: Rett syndrome therapeutic development. Trends Pharmacol Sci, 2019; 40:233–236.
29.
PolsterT: Individualized treatment approaches: fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav, 2019; 91:99–102.
30.
An-Sofie SchoonjansA-S, LagaeL, CeulemansB: Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord, 2015; 8:328–338.
31.
HaugenIK, MathiessenA, Slatkowsky-ChristensenB, et al.: Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype?. Osteoarthritis Cartilage, 2016; 24:647–654.
32.
SaviolaG, Abdi-AliL, PovinoMR, et al.: Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation). Clin Rheumatol, 2017; 36:2343–2350.
33.
SternAG, de CarvalhoMR, BuckGA, et al.: Association of erosive hand osteoarthritis with a single nucleotide polymorphism on the gene encoding interleukin-1 beta. Osteoarthritis Cartilage, 2003; 11:394–402.
34.
FanningPJ, WalcottME, O'ConnellSL, et al.: Montelukast sodium as a treatment for experimental osteoarthritis in mice. Osteoarthritis Cartilage, 2009; 17(Suppl 1):S283–S284.
35.
SaviolaG, Abdi-AliL, CampostriniL, et al.: Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. Mod Rheumatol, 2012; 22:256–263.
ŠkerlováJ, UnterlassJ, GöttmannM, et al.: Crystal structures of human PAICS reveal substrate and product binding of an emerging cancer target. J Biol Chem, 2020; 295:11656–11668.
38.
KellerKE, DoctorZM, DwyerZW, LeeYS: SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol Cell, 2014; 53:700–709.
39.
KelleyWN, WyngaardenJB: Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells. J Clin Invest, 1970; 49:602–609.
40.
PiccininE, VillaniG, MoschettaA: Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol, 2019; 16:160–174.
41.
CaveMC, ClairHB, HardestyJE, et al.: Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta, 2016; 1859:1083–1099.
42.
WallaceMC, PreenD, JeffreyGP, AdamsLA: The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol, 2015; 9:765–779.
43.
GorainB, ChoudhuryH, YeeGS, BhattamisraSK: Adenosine Receptors as Novel Targets for the Treatment of Various Cancers. Curr Pharm Des, 2019; 25:2828–2841.
44.
CongreveM, BrownGA, BorodovskyA, LambML: Targeting adenosine A(2A) receptor antagonism for treatment of cancer. Expert Opin Drug Discov, 2018; 13:997–1003.
45.
BeavisPA, MilenkovskiN, HerdersonMA, et al.: Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res, 2015; 3:506–517.
46.
LoiS, PommeyS, Haibe-KainsB, et al.: CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A, 2013; 110:11091–11096.
